John Butler

John Butler is a mission-driven entrepreneur in the biotech sector, specifically focused on cancer diagnostics. His personal experience with his wife's late-stage metastatic cancer diagnosis motivated him to found QuantumCyte, Inc., dedicating his work to advancing cancer research and clinical testing to help patients find effective drug therapies. squarespace+2

With over 30 years of experience, John has a deep background in advanced technology development for genomics and biotech applications. His expertise spans PCR-based applications, human genome studies, and transitioning technologies from concept through manufacturing in high-throughput environments, demonstrated through his roles at Pacific Biosciences, Thermo Fisher Scientific, and Protogene Labs. squarespace+1

As CEO/CSO of QuantumCyte, John leads the development of the QCPRECISE platform, an innovative system that integrates digital pathology with molecular analysis (NGS). This technology aims to improve the specificity and signal-to-noise ratio in studying drug responses in cancer cells by enabling precise spatial microdissection and enhancing nucleic acid purity from tissue biopsies, thereby accelerating biomarker validation and targeted therapy development. pmwcintl+6

John has an academic affiliation with Stanford University School of Medicine, where he served as a Visiting Scholar in the Davis Lab from 2012 to 2014, and later as Director of Process Development from 2014 to 2016. squarespace